← Leaderboards
Lianwang Guo
University Of Wisconsin-Madison
$8,850,010
Attributed
$14,920,730
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,920,730 · 9
By mechanism
R01$14,920,730 · 9
Top collaborators
- Shaoqin - Gong14 shared
- K Craig Kent14 shared
- Coleen A Mcnamara2 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Shaoqin - Gong$18,047,338
- Christian Capitini$4,273,809
Others in their field
Top investigators on “Knock-Out”
- Kc Kent Lloyd · University Of California At Davis$56,471,080
- Gary K Owens · University Of Virginia$28,774,798
- Arlene H Sharpe · Harvard Medical School$28,562,987
- C Ronald Kahn · Joslin Diabetes Center$26,818,970
- David Manuel Valenzuela · Regeneron Pharmaceuticals, Inc.$25,346,919
- Pieter J. De Jong · Children'S Hospital &Res Ctr At Oakland$22,990,292
Research focus
Knock-OutMediatingIn VivoSmooth Muscle MyocytesLeadGenesCellsProteinsPreventMortalityIn VitroInflammationBlood VesselsOperative Surgical ProceduresArteriesInnovationCardiovascular DiseasesMouse ModelMorbidity - Disease RateEffective TherapyHyperplasiaOverexpressionPharmaceutical PreparationsMolecular
Grant awards (33)
Targeted suppression of ALDH1A3 for endothelial beneficial management of restenosis after vascular surgery$719,626
R01 · FY2025 · HL · contact PI
Epigenetic targeting and nanoplatform-enabled local drug delivery - a two-pronged approach to stenosis prevention after vascular surgery$713,869
R01 · FY2025 · HL · contact PI
Targeted approach to the mitigation of abdominal aortic aneurysm$709,437
R01 · FY2025 · HL · contact PI
Mechanistic and Translational Determination of PERK-targeting Strategies for Non-surgical Management of Abdominal Aortic Aneurysm$690,384
R01 · FY2025 · HL
Epigenetic targeting and nanoplatform-enabled local drug delivery - a two-pronged approach to stenosis prevention after vascular surgery$729,244
R01 · FY2024 · HL · contact PI
Targeted approach to the mitigation of abdominal aortic aneurysm$724,978
R01 · FY2024 · HL · contact PI
Targeted suppression of ALDH1A3 for endothelial beneficial management of restenosis after vascular surgery$719,626
R01 · FY2024 · HL
Mechanistic and Translational Determination of PERK-targeting Strategies for Non-surgical Management of Abdominal Aortic Aneurysm$678,529
R01 · FY2024 · HL
Master epigenetic regulators and retinal degenerative disease$390,895
R01 · FY2022 · EY · contact PI
Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular Surgery$634,517
R01 · FY2021 · HL
Master epigenetic regulators and retinal degenerative disease$390,598
R01 · FY2021 · EY · contact PI
Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular Surgery$595,265
R01 · FY2020 · HL · contact PI
Master epigenetic regulators and retinal degenerative disease$345,437
R01 · FY2020 · EY · contact PI
Master epigenetic regulators and retinal degenerative disease$38,382
R01 · FY2020 · EY · contact PI
Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular Surgery$595,265
R01 · FY2019 · HL · contact PI
Master epigenetic regulators and retinal degenerative disease$389,328
R01 · FY2019 · EY · contact PI
BET Bromodomain proteins as Novel Epigenetic Targets for prevention of Intimal Hyperplasia after Vascular Surgery$314,880
R01 · FY2019 · HL · contact PI
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction$313,866
R01 · FY2019 · HL · contact PI
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction$168,300
R01 · FY2019 · HL
BET Bromodomain proteins as Novel Epigenetic Targets for prevention of Intimal Hyperplasia after Vascular Surgery$81,570
R01 · FY2019 · HL · contact PI
Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular Surgery$609,265
R01 · FY2018 · HL
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction$483,556
R01 · FY2018 · HL
BET Bromodomain proteins as Novel Epigenetic Targets for prevention of Intimal Hyperplasia after Vascular Surgery$396,450
R01 · FY2018 · HL · contact PI
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction$496,555
R01 · FY2017 · HL
BET Bromodomain proteins as Novel Epigenetic Targets for prevention of Intimal Hyperplasia after Vascular Surgery$408,000
R01 · FY2017 · HL · contact PI
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstruction$553,250
R01 · FY2016 · HL
BET Bromodomain proteins as Novel Epigenetic Targets for prevention of Intimal Hyperplasia after Vascular Surgery$378,058
R01 · FY2016 · HL · contact PI
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina$171,375
R01 · FY2016 · EY · contact PI
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina$165,000
R01 · FY2016 · EY · contact PI
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina$329,647
R01 · FY2015 · EY · contact PI
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina$329,647
R01 · FY2014 · EY · contact PI
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina$319,556
R01 · FY2013 · EY · contact PI
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the Retina$336,375
R01 · FY2012 · EY · contact PI